Somatostatinoma

Somatostatinoma is a rare pancreatic neuroendocrine tumor that secretes excess somatostatin, and USMLE Step 1 almost never asks you to diagnose it from scratch — instead, it presents the triad (diabetes, steatorrhea, gallstones) and expects you to reconstruct why each feature occurs. Students who memorize the triad without understanding the mechanistic links fail on these questions. Every feature flows directly from somatostatin's normal inhibitory actions: suppressed insulin drives diabetes, suppressed CCK and pancreatic enzymes drive steatorrhea, and suppressed CCK-driven gallbladder contraction causes bile stasis and gallstones.

What makes this tricky is that students either blank on the triad entirely or know it but can't explain the connection between the hormone and the symptom. The exam rewards mechanistic reasoning: why does somatostatinoma cause steatorrhea? Because somatostatin inhibits pancreatic enzyme secretion AND reduces bile flow (via CCK suppression), so fat can't be digested or absorbed. Why gallstones? Because CCK normally drives gallbladder contraction — suppress CCK, the gallbladder stagnates, bile concentrates, stones form. Why diabetes? Because somatostatin inhibits insulin (and glucagon, but the net effect is hyperglycemia). If you can reconstruct the triad from first principles, you're prepared for any angle the exam can throw.

The other confusion point involves octreotide. Students sometimes wonder whether giving a somatostatin analog to someone with somatostatinoma would help or hurt. That question is a trap: somatostatinoma already produces excess somatostatin, so octreotide wouldn't add therapeutic benefit the way it does for insulinomas or carcinoid tumors. USMLE Step 1 may test this contrast — octreotide is a treatment tool for other neuroendocrine tumors precisely because it mimics what somatostatinoma does pathologically.